Delivering more for human health and beyond
Medlab Clinical (ASX: MDC) is an Australian publicly listed biotechnology company with a global market opportunity. Our team of scientists, researchers and doctors are dedicated to building products that are scientifically optimised for a better life, specialising in oncology and enhanced drug delivery.
Medlab has a portfolio of novel cannabinoid-based assets enhanced by our leading drug delivery platform. Our lead drug candidate, NanaBis™, is an opioid alternative for cancer-induced pain management, with company-making potential and a global market opportunity.
Core to our value proposition is NanoCelle®, our patented sub-micron drug delivery platform that vastly improves drug solubility issues and enables faster absorption and metabolism of active ingredients. NanoCelle® underpins our growth strategy by offering near-term partnering opportunities whilst enhancing our pharma portfolio.
Investment Highlights
- Patented NanoCelle® drug delivery platform with value creation optionality, enhancing our product portfolio whilst offering near term partnering opportunities
- World-class Board, management and scientific consulting team with strong experience bringing novel therapeutics to market
- Scientifically optimised portfolio of cannabinoid therapeutics addressing a global unmet need in oncology areas including pain management
- Lead candidate NanaBis™ Phase I/II primary and secondary endpoints met in bone cancer patients, replicated in a real-world observational study. Stage III commencing in near-term with robust and clear drug pathway in US, EU and Australia
- NanaBis™ proof of concept established and early revenue being generated via Special Access Scheme
Have an investor relationship question, you can book a meeting with our CEO, Dr Sean Hall
Sign up for Investor Updates
Stay up-to-date with the latest investor news, presentations and videos from Medlab sent directly to your email address.
Latest Investor News
Medlab Clinical Ltd (ASX:MDC) sells its Australian nutraceutical business to PharmaCare
We would like to inform you that Medlab Clinical Ltd (ASX:MDC) is very pleased to announce the sale of the Australian-only part of its nutraceutical business to PharmaCare, a well-established and respected Australian health & wellness company.
2021-10-27
Annual Message to Shareholders October 2021
Medlab Confirms US Patent Office has approved NanoCelle® patent for USA territories this is in addition to the receipt of a further 42 worldwide patents.
2021-10-13
Edison Group – Executive interview with CEO, Dr Sean Hall
In this video, Dr Sean Hall, Medlab’s co-founder and CEO, introduces us to Medlab and its lead programmes and discusses what we can expect from this fast-growing company over the coming months.
2021-07-29
Medlab Clinical talks upcoming Phase III NanaBis trial and NanoCelle partnering opportunities
Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortest time possible. He adds that they've identified multiple revenue-generating partnering opportunities for its NanoCelle® drug delivery platform which he says can improve the efficacy of multiple medicines and therapeutics.
2021-06-24
Jefferies Healthcare Conference - 2021
Medlab outlines its growth strategy for US and global investors at the prestigious annual Jefferies Healthcare Conference.
2021-06-01
Small Caps interview of CEO Sean Hall
Small Caps interviews the CEO of Medlab, Sean Hall about the future of NanoCelle® drug delivery technology and pharmaceutical portfolio
2021-04-22
Medlab mixes reality with Microsoft
Read the three featured stories from Microsoft about Medlab's adoption of mixed reality solutions including HoloLens 2 head-mounted devices with Dynamics 365 Remote Assist, to help combat the pandemic by improving time to market and guaranteeing crucial business progression.
2021-04-14
NanaBis demonstrates continued improvement in pain scores
The first cohort of Observational Study patients completing 12-month treatment with NanaBis™ demonstrated continued improvement in pain scores.
2021-04-12
Medlab to be granted European patent for NanoCelle® drug delivery platform
European Patent Office issues Notice of Intention to grant Medlab Clinical patent for NanoCelle® drug delivery platform
2021-04-07
Novartis’ Managing Director of Oncology (ANZ/NZ) joins Medlab Clinical board
Medlab Clinical appoints Novartis' Managing Director of Oncology for Australia and New Zealand as Non-Executive Director.
2021-03-23
Medlab Clinical raises $15 million and Leading Executive Joins Board
Medlab Clinical successfully raised $15 million to help fund its upcoming Phase III clinical trial and has extended its board expertise with the appointment of leading pharmaceutical executive Mrs Cheryl Maley.
2021-03-19
Medlab Clinical looks for $15 million equity injection
Medlab clinical looks to raise $15 million to fund its Phase III trial. Read more here.
2021-03-17
Medlab Clinical partners with Arrotex
Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies
2021-02-18
Medlab to confirm NanaBis’ potential as non-opioid analgesic in phase III trial
Read the write up from Small Caps about Medlab's non-opioid pain treatment
2021-01-27
Ausbiz interview of CEO Sean Hall
Ausbiz interviews the CEO of Medlab, Sean Hall about the future of Medlab
2021-01-27
Ausbiz interview
Ausbiz interviews the CEO of Medlab, Sean Hall about the future of Medlab
2020-12-02
Switzer Investor Day
4th Small and Micro-Cap Virtual Investor Day
2020-12-02
Nanabis Presentation
Learn more about NanaBis and the significant opportunity ahead
2020-09-01
StockPal Webinar
In this part two of a four-part webinar recap, Sean Hall, Chief Executive Officer and Managing Director of Medlab (ASX:MDC) presented on the company’s latest announcements and updates while answering some questions during the Q&A session at the end.
2020-08-11
Page No.
